WuXi XDC Out-Licenses WuXiTecan-2 Payload-Linker Technology Platform to Ona Therapeutics to Advance Novel ADC Research and Development

PartnershipWuXiTecan-2Positive

AI Analysis

Summary

WuXi XDC out-licensed its WuXiTecan-2 payload-linker technology platform to Ona Therapeutics for advancing antibody-drug conjugate research and development. This partnership expands WuXi XDC's technology monetization in the ADC space.

Importance:6/10

Sentiment:

0.60

licensingADCpayload-linker technologycollaborationCRDMO

Related Companies

$WXI

Read the original article

Published by PR Newswire Biotech on September 17, 2026 8:09 AM

Read Original